NCT00250991

Brief Summary

The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P75+ for phase_1 stroke

Timeline
Completed

Started Jul 2003

Longer than P75 for phase_1 stroke

Geographic Reach
1 country

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2003

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

November 7, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 9, 2005

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2007

Completed
Last Updated

May 8, 2009

Status Verified

May 1, 2009

First QC Date

November 7, 2005

Last Update Submit

May 7, 2009

Conditions

Keywords

strokeintegrilineptifibatideactivaserecombinant tissue plasminogen activatorrt-PArecombinant t-PASPOTRIAS

Outcome Measures

Primary Outcomes (2)

  • The primary safety endpoint in this safety study will be the incidence of symptomatic intracranial hemorrhage .

    within 36 hours

  • The primary measure of early beneficial drug activity will be the incidence of early neurological improvement, as measured by the NIHSSS </= 2

    at 24 hours from symptom onset

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have a serious measurable neurological deficit on the NIH Stroke Scale due to focal brain ischemia.
  • An NIH Stroke Scale score \>5 at the time that intravenous study drug is begun.
  • Age: 18 through 80 years (i.e. candidates must have had their 18th birthday, but not had their 81st birthday).
  • Intravenous therapy must be initiated within 3 hours of onset of stroke symptoms.

You may not qualify if:

  • History of stroke in the past 3 months.
  • Previous intra-cranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation
  • Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT scan is normal
  • Hypertension at time of treatment; systolic BP \> 185 or diastolic \> 110 mmHg or aggressive measures to lower blood pressure to below these limits are needed.
  • Presumed septic embolus
  • Presumed pericarditis including pericarditis after acute myocardial infarction
  • Recent (within 30 days) surgery or biopsy of parenchymal organ
  • Recent (within 30 days) trauma, with internal injuries or ulcerative wounds
  • Recent (within 90 days) severe head trauma or head trauma with loss of consciousness
  • Any active or recent (within 30 days) serious systemic hemorrhage
  • Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or oral anticoagulant therapy with prothrombin time greater than 15 or INR \> 1.4
  • Baseline lab values: positive urine pregnancy test, glucose \< 50 or \> 400 mg/dl, platelets \<100,000 /mm3, Hct \<25 %, or creatinine \> 4 mg/dl
  • Ongoing renal dialysis, regardless of creatinine
  • If heparin has been administered within 48 hours, the patient must have a normal partial thromboplastin time (PTT)
  • Arterial puncture at a non-compressible site or a lumbar puncture in the previous 7 days
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Barrow Neurologic Institute, St. Joseph's Hospital and Medical Center, 350 West Thomas Rd

Phoenix, Arizona, 85013, United States

Location

University of California, Los Angeles, UCLA Medical Center, 10833 Le Conte Ave.

Los Angeles, California, 90024, United States

Location

Santa Monica-UCLA Medical Center, 1250 16th Street

Santa Monica, California, 90404, United States

Location

St. John's Health Center, 1328 22nd St

Santa Monica, California, 90404, United States

Location

St. Elizabeth Medical Center South, One Medical Village Drive

Edgewood, Kentucky, 41017, United States

Location

Jewish Hospital Louisville, Jewish Hospital Healthcare Services Inc., 200 Abraham Flexner Way

Louisville, Kentucky, 40202, United States

Location

University of Michigan, University of Michigan Health System, 1500 E. Medical Center Drive, TC B1354, Box 0303

Ann Arbor, Michigan, 48109-0303, United States

Location

Long Island Jewish, North Shore-Long Island Jewish Health System, 270-05 76 Avenue

New Hyde Park, New York, 11040, United States

Location

The Christ Hospital, 2139 Auburn Ave.

Cincinnati, Ohio, 45219, United States

Location

University of Cincinnati, University Hospital, 234 Goodman Ave.

Cincinnati, Ohio, 45219, United States

Location

Good Samaritan Hospital, 375 Dixmyth Ave.,

Cincinnati, Ohio, 45220-2489, United States

Location

The Jewish Hospital of Cincinnati, 4777 East Galbraith Rd,

Cincinnati, Ohio, 45236, United States

Location

Mercy Hospital, Western Hills, 3131 Queen City Ave.

Cincinnati, Ohio, 45238, United States

Location

Mercy Hospital, Mt Airy, 2446 Kipling Ave.

Cincinnati, Ohio, 45239, United States

Location

Bethesda North Hospital, 10500 Montgomery Rd

Montgomery, Ohio, 45242, United States

Location

Lehigh Valley Hospital, 1200 South Cedar Crest Blvd

Allentown, Pennsylvania, 18103, United States

Location

University of Pennsylvania, University of Pennsylvania Medical Center, 3400 Spruce Street

Philadelphia, Pennsylvania, 19104, United States

Location

Brown University, Rhode Island Hospital, 593 Eddy St.

Providence, Rhode Island, 02903, United States

Location

Vanderbilt University, University Hospital, 1211 22nd Ave. S.

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Stroke

Interventions

Tissue Plasminogen ActivatorEptifibatide

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Serine EndopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesSerine ProteasesPlasminogen ActivatorsBlood Coagulation FactorsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsBiological FactorsPeptides, CyclicPeptides

Study Officials

  • Arthur Pancioli, MD

    University of Cincinnati College of Medicine, Department of Emergency Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 7, 2005

First Posted

November 9, 2005

Study Start

July 1, 2003

Study Completion

July 1, 2007

Last Updated

May 8, 2009

Record last verified: 2009-05

Locations